98%
921
2 minutes
20
Introduction: Carotid artery revascularization has traditionally been performed by either a carotid endarterectomy or carotid artery stent. Large data analysis has suggested there are differences in perioperative outcomes with regards to race, with non-White patients (NWP) having worse outcomes of stroke, restenosis and return to the operating room (RTOR). The introduction of transcarotid artery revascularization (TCAR) has started to shift the paradigm of carotid disease treatment. However, to date, there have been no studies assessing the difference in postoperative outcomes after TCAR between racial groups.
Methods: All patients from 2016 to 2021 in the Vascular Quality Initiative who underwent TCAR were included in our analysis. Patients were split into two groups based on race: individuals who identified as White and a second group that comprised all other races. Demographic and clinical variables were compared using Student's t-Test and chi-square test of independence. Logistic regression analysis was performed to determine the impact of race on perioperative outcomes of stroke, myocardial infarction (MI), death, restenosis, RTOR, and transient ischemic attack (TIA).
Results: The cohort consisted of 22,609 patients: 20,424 (90.3%) White patients and 2185 (9.7%) NWP. After adjusting for sex, diabetes, hypertension, coronary artery disease, history of prior stroke or TIA, symptomatic status, and high-risk criteria at time of TCAR, there was a significant difference in postoperative stroke, with 63% increased risk in NWP (odds ratio = 1.63, 95% confidence interval: 1.11-2.40, P = 0.014). However, we found no significant difference in the odds of MI, death, postoperative TIA, restenosis, or RTOR when comparing NWP to White patients.
Conclusions: This study demonstrates that NWP have increased risk of stroke but similar outcomes of death, MI, RTOR and restenosis following TCAR. Future studies are needed to elucidate and address the underlying causes of racial disparity in carotid revascularization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2024.04.062 | DOI Listing |
Cardiovasc Revasc Med
September 2025
Division of Vascular Surgery, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address:
Background: protamine sulfate is used to reduce bleeding risk after Carotid Artery Stenting (CAS), but its efficacy in personalized patient settings remains underexplored. This study aims to identify factors associated with greater benefits from protamine sulfate following CAS.
Methods: A retrospective review of Vascular Quality Initiative (VQI) data (2016-2022) identified patients undergoing CAS, divided into Transfemoral CAS (TF-CAS) and Transcarotid artery revascularization (TCAR) groups.
Acad Radiol
September 2025
Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan (J.Y.H., C.L.K., K.L.C.); College of Medicine, National Taiwan University, Taipei, Taiwan (J.Y.H., C.K.H., K.L.C., Y.W.W.); Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (C.K
Rationale And Objectives: The prognostic implications of myocardial perfusion imaging (MPI) are imperative to provide proper management of coronary artery disease (CAD). This study aimed to quantify the long-term prognostic value of MPI under routine clinical conditions.
Materials And Methods: This single-center retrospective cohort study evaluated all-cause mortality and cause-specific survival according to MPI findings in patients with suspected or known CAD who underwent diagnostic evaluation or assessment of myocardial ischemia and viability in a tertiary referral cardiovascular center.
Eur J Vasc Endovasc Surg
September 2025
Department of Neurology, Yuan Rung Hospital, Changhua 510001, Taiwan; Department of Nursing, College of Nursing and Health, Da-Yeh University, Changhua 515006, Taiwan. Electronic address:
J Cardiovasc Surg (Torino)
September 2025
Catheterization Laboratory, Montevergine Clinic, Mercogliano, Avellino, Italy -
Background: Lower extremity arterial disease is a prevalent vascular condition leading to ischemic symptoms and increased risk of cardiovascular events. Drug-eluting stents have improved outcomes by reducing restenosis, with sirolimus emerging as a promising alternative to paclitaxel due to its safer profile. This study evaluates the efficacy and safety of novel polymer-free Amphilimus formulation (Sirolimus + fatty acid) eluting self-expanding stent in the treatment of femoropopliteal disease in a real-world population.
View Article and Find Full Text PDFCardiovasc Interv Ther
September 2025
Division of Cardiovascular Medicine, Toyohashi Heart Center, Aichi, Japan.
The outcome of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) is still controversial for patients with left main coronary artery (LMCA) disease. This multicenter cohort study aimed to evaluate the clinical outcomes of LMCA disease patients who underwent PCI or CABG. We reviewed 875 consecutive patients diagnosed with LMCA disease between January 2009 and December 2020 who underwent coronary revascularization by PCI (n = 404) or CABG (n = 471).
View Article and Find Full Text PDF